Middle Eastern Penny Stocks With Market Caps Over US$60M To Watch
As the Middle Eastern markets navigate the complexities of global trade tensions, particularly between the U.S. and China, investors are keeping a close eye on regional indices that have shown mixed performances. In this context, penny stocks—though an older term—continue to represent smaller or less-established companies that might offer significant value to discerning investors. By focusing on those with solid financials and growth potential, these stocks can provide unique opportunities for those looking beyond traditional investment options.
Name
Share Price
Market Cap
Financial Health Rating
Thob Al Aseel (SASE:4012)
SAR4.13
SAR1.58B
★★★★★★
Keir International (SASE:9542)
SAR3.92
SAR474M
★★★★★☆
Dna Group (T.R.) (TASE:DNA)
₪0.999
₪123.04M
★★★★★★
Alarum Technologies (TASE:ALAR)
₪2.446
₪171.3M
★★★★★★
Oil Refineries (TASE:ORL)
₪0.922
₪2.87B
★★★★★☆
Tgi Infrastructures (TASE:TGI)
₪2.222
₪165.19M
★★★★★★
Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC)
AED0.709
AED425.78M
★★★★★★
Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR)
AED3.40
AED390.39M
★★★★★★
E7 Group PJSC (ADX:E7)
AED1.03
AED2.1B
★★★★★★
Dubai Investments PJSC (DFM:DIC)
AED2.36
AED10.03B
★★★★☆☆
Click here to see the full list of 95 stocks from our Middle Eastern Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Ihlas Yayin Holding A.S. operates in Turkey through its subsidiaries, focusing on media, publishing, and advertising businesses with a market cap of TRY940.50 million.
Operations: The company generates revenue from several segments, including Journalism and Printing Works (TRY1.77 billion), News Agencies (TRY389.08 million), and TV Services and Other (TRY318.35 million).
Market Cap: TRY940.5M
Ihlas Yayin Holding's financial landscape presents a mixed picture for investors considering penny stocks. The company's revenue of TRY2.48 billion reflects a slight decline from the previous year, while it remains unprofitable with a net loss of TRY227.23 million. Despite this, the company has more cash than debt and its short-term assets exceed short-term liabilities, indicating some financial resilience. However, its cash runway is less than one year if free cash flow continues to shrink at historical rates. The board's average tenure of 5.3 years suggests experienced governance amidst these challenges.
Jump into the full analysis health report here for a deeper understanding of Ihlas Yayin Holding.
Gain insights into Ihlas Yayin Holding's historical outcomes by reviewing our past performance report.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Metro Ticari ve Mali Yatirimlar Holding A.S. operates as a diversified holding company with various business interests, and it has a market capitalization of TRY1.33 billion.
Operations: The company generates revenue primarily from its Transportation - Railroads segment, amounting to TRY28.73 million.
Market Cap: TRY1.33B
Metro Ticari ve Mali Yatirimlar Holding, with a market cap of TRY1.33 billion, operates without debt and has not diluted shareholders recently. Despite generating TRY28.73 million in revenue primarily from its railroads segment, the company remains unprofitable with a significant net loss of TRY1,085.84 million for the past year. Its short-term assets exceed liabilities but fall short against long-term obligations of TRY219.6 million. The firm boasts a cash runway exceeding three years if current free cash flow remains stable, supported by an experienced board averaging 4.8 years in tenure amidst financial challenges and volatility stability over the past year.
Unlock comprehensive insights into our analysis of Metro Ticari ve Mali Yatirimlar Holding stock in this financial health report.
Assess Metro Ticari ve Mali Yatirimlar Holding's previous results with our detailed historical performance reports.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Bonus BioGroup Ltd. is a clinical-stage biotechnology company focused on developing tissue engineering and cell therapy products, with a market cap of ₪230.08 million.
Operations: Bonus BioGroup Ltd. currently has no reported revenue segments.
Market Cap: ₪230.08M
Bonus BioGroup Ltd., with a market cap of ₪230.08 million, is a pre-revenue clinical-stage biotechnology company focusing on tissue engineering and cell therapy products. The firm recently secured FDA clearance for a Phase III clinical study of MesenCure™, targeting respiratory distress in severely ill patients. Despite its potential, the company faces financial challenges, including short-term assets that do not cover liabilities and a cash runway limited to three months before recent capital raising efforts. While debt-free and led by an experienced management team, Bonus BioGroup's stock remains highly volatile with no significant revenue streams yet established.
Click here and access our complete financial health analysis report to understand the dynamics of Bonus BioGroup.
Gain insights into Bonus BioGroup's past trends and performance with our report on the company's historical track record.
Gain an insight into the universe of 95 Middle Eastern Penny Stocks by clicking here.
Curious About Other Options? This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IBSE:IHYAY IBSE:METRO and TASE:BONS.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Financial Experts: These Are the Top Mistakes Americans Make When Investing in the Stock Market
There's no reason you should lose money investing in stocks, considering that the markets always move higher over time. This decade alone, the S&P 500 has risen by about 88%. Just investing in an S&P 500 fund could have helped any investor generate solid profits. But a lot of investors still take a beating on Wall Street because they make common mistakes that can be easily avoided. Read Next: Check Out: Here are the top mistakes Americans make when investing in the stock market, according to three financial experts contacted by GOBankingRates. Also see the No. 1 mistake Americans make with their Roth IRAs, according to experts. Misjudging risk was cited by Christine Chase, vice president and financial consultant at Fidelity Investments. More precisely, she cited a tendency to misjudge risk tolerance, which means too many investors either take on too much risk or are too conservative. Both extremes can negatively impact your return. 'Excessive risk can lead to emotional decision-making and panic-selling during market downturns, while being too conservative may prevent your portfolio from growing enough to meet long-term goals or keep pace with inflation,' Chase said. To help manage risk and navigate the market's ups and downs, she recommended maintaining a well-diversified portfolio and working with a financial professional. Be Aware: Anthony Grosso, a New York-based financial strategist and mortgage loan originator, told GOBankingRates the biggest mistake he sees people make is 'blindly trusting the news' when investing. He learned this lesson himself as a younger investor. 'What I learned fast is that by the time something makes [it to the news], the market has already reacted,' Grosso said. 'The news isn't meant to educate — it's there to get clicks and views. They will spin a story, beat a topic to death until you're panicked or euphoric, and both of those times are when you make emotional decisions which are the worst ones.' If you do watch the news, he recommended doing so with a healthy dose of skepticism. 'Try to get reports of the actual data — not someone's opinion on the data,' Grosso said. 'Learn to make your own opinions and it will give you the confidence to have a plan and stick with it.' Not cutting losses is a mistake that happens a lot, according to Edward Corona, a Florida-based trader and publisher of The Options Oracle Newsletter. In fact, it happened to him early in his career. 'I'd hang onto trades way too long, convincing myself they'd bounce back,' Corona told GOBankingRates. 'I'd look at charts, squint real hard, and try to find a reason to stay in. You know the drill: 'It's just a dip,' or 'I'm down, but not that much…'' The problem, he said, is that small losses can 'turn into portfolio wreckers real fast' if you stay with a sinking stock too long. His suggestion is to have a plan in place before hitting the 'buy' button and sticking with that plan when an investment goes south. 'I'm going to have a predetermined 'stop loss' and 'take profit' level before I enter the trade, which would be based on a support level,' Corona said. 'If it breaks below that level, I will exit the trade and redeploy the capital elsewhere.' More From GOBankingRates The 10 Most Reliable SUVs of 2025 This article originally appeared on Financial Experts: These Are the Top Mistakes Americans Make When Investing in the Stock Market Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Beaten-Down Dividend Stocks to Buy Now and Hold at Least a Decade
Whether they want rapid payout growth or a high yield that rises slowly, income focused investors can find what their looking for in the healthcare sector. UnitedHealth Group stock has been offering a 3% yield, and it's payout has grown by leaps and bounds in recent years. Pfizer offers a dividend yield over 7%, but it's payout probably won't rise very fast in the decade ahead. 10 stocks we like better than UnitedHealth Group › Investors seeking high yields or rapid dividend growth can find what they're looking for from a reliable pair of stocks in the healthcare sector. UnitedHealth Group's (NYSE: UNH) recent CEO departure and corresponding suspension of forward guidance ended a long stretch of strong returns. Now you can buy the stock for less than half the peak price it reached last October. Incoming competition for Pfizer's (NYSE: PFE) top-selling drugs has knocked the pharmaceutical stock down more than 60% from its all-time high. Pfizer and UnitedHealth Group are both known for reliable annual dividend payout raises. You wouldn't know it by looking at their stock prices, but there's a good chance that both can continue their streaks for at least another decade. If there's one thing the stock market hates, it's uncertainty. UnitedHealth Group investors learned this the hard way when the company suspended forward-looking earnings guidance and bid farewell to its CEO, Andrew Witty, in May. To explain the earnings guidance suspension, UnitedHealth Group's new CEO, John Rex, told investors the new members it signed up last year required more care than expected. Medicare Advantage members were also using more services than anticipated. He didn't go into detail, but said there are indications that the higher utilization trend could broaden. Ever since the Affordable Care Act, insurers have been required to spend at least 85% of the premiums they receive on medical expenses. Raising premiums to a level that can absorb those expenses without going too far is getting trickier. From 2023 through 2032, the Centers for Medicare and Medicaid Services (CMS) expects the national health expenditure to rise by 5.6% annually. Unfortunately, some areas are rising at a faster pace. For example, hospital expenditures soared 10.4% in 2023. UnitedHealth Group may have misjudged the amount of care a slew of recently added customers would require, but there's a good chance it can right the ship under new leadership. Its biggest competitor, CVS Health, made hardly any additions to its membership roster over the past year. Being careful about which patients it enrolls worked out well. Instead of suspending its 2025 outlook, CVS Health raised its 2025 adjusted earnings guidance range by 3.8% in May. Rising reimbursement rates from healthcare providers are a hassle for UnitedHealth Group, but it's only a matter of time before it passes those costs on to health plan sponsors who have limited options. In 2023, UnitedHealth Group's Optum Health segment employed or affiliated with 10% of all physicians in the U.S. As the country's largest employer of physicians, it can do more to control medical expenses than its smaller peers. As the leading medical benefits management business, UnitedHealth Group's business could keep growing along with America's national health expenditure. The company's been able to hike its dividend by 77% over the past five years. Despite rapid payout raises, it needed just 31% of the free cash flow it's generated over the past year to meet its dividend commitment. Payout bumps could be slow over the next year or two as it finds appropriate prices for its health plans, but a return to its rapid pace seems likely. At recent prices, UnitedHealth Group offers a 3% dividend yield. If the company maintains its payout growth rate, folks who buy the beaten-down stock could begin receiving a double-digit yield on cost in about a decade. If you still have a lot of runway ahead of retirement, this could be a great portfolio addition. Folks who want to draw from their retirement savings sooner rather than later might want to check out Pfizer. Shares of the pharmaceutical giant are down about 62% from a peak they set in 2022. The stock price is down but the company has raised its payout every year since 2009. At its beaten-down price, it offers a huge 7.4% dividend yield. Pfizer is down partly because sales of its COVID-19 products have collapsed and partly because sales of several blockbusters are nearing patent cliffs. Although COVID-19 product sales collapsed, trailing-12-month revenue is up by 81% over the past five years. Patent expirations for several of Pfizer's top-selling treatments will make growing the overall operation extra challenging over the next five years. In January, Albert Bourla, the CEO, told investors a loss of exclusivity wave could cost the company $17 billion to $18 billion in annual revenue by the end of 2028. Fortunately, Pfizer reinvested heaps of the profits that its COVID-19 products generated. Management expects acquired products to deliver $20 billion of revenue annually by 2030. In other words, the company probably has the means to overcome its patent cliff and continue raising its dividend payout, albeit slowly, in the decade ahead. Pharmaceutical product launches usually aren't as predictable as investors want them to be. With an enormous global salesforce already in place, though, Pfizer's launches are more predictable than most. While there's a chance the company could lower its payout in a few years, continued payout raises in the decade ahead seem far more likely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Cory Renauer has positions in CVS Health. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy. 2 Beaten-Down Dividend Stocks to Buy Now and Hold at Least a Decade was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Warren Buffet's Retirement: 5 Smart Money Moves That Made Him His Massive Fortune
Warren Buffet is one of the richest men in the world, with a current net worth of approximately $157 billion, according to Forbes. As the CEO of Berkshire Hathaway for 60 years, Buffett has been the perfect case study for how some relatively straightforward business principles can result in massive success. Discover More: Read Next: While Buffett certainly has some advantages that most average investors don't — from incredible stock-picking acumen to nearly unlimited capital reserves — the principles that he follows are basic enough for anyone to follow and understand. With news of Buffett's retirement buzzing, here's a look at five smart money moves from the Oracle of Omaha that you can adapt to use at a personal level. Berkshire Hathaway is a conglomerate of hundreds of businesses. Essentially, it acts as a holding company for Buffett's investment choices. To make it into Berkshire's portfolio, a company has to be a quality business trading at a discount. In most cases, this means it's priced below what Buffett determines to be its 'intrinsic value.' This provides the opportunity for future profits when the market 'correctly' reprices the business. It's true that the average investor likely doesn't have the time or talent to analyze a company's cash flows and future earnings to derive an 'intrinsic value.' But the principle behind the process remains applicable to all investors and can be distilled down to this simple strategy: Buy low, sell high. Trending Now: Buffett has been famously quoted as saying that his favorite holding period for a stock is 'forever.' Buffett is the anti-trader, a long-term investor who gives his stocks years if not decades to turn huge profits. This gives Buffett the time to enjoy the benefits of compound interest and also to take advantage of long-term capital gains tax rates. These are both fundamental investment concepts that anyone can adopt. One of Buffett's driving investment principles is that you should always keep cash reserves on hand so that you can take advantage of any market opportunities. Now, it's unlikely that you'll ever amass the whopping $334 billion in cash reserves that Berkshire Hathaway currently holds, but the idea behind amassing cash reserves applies to everyone. While you shouldn't hold too much cash in your portfolio, having some on hand allows you to be flexible and adapt to the current market environment. Buffett is far from the only financial expert to recommend understanding what you buy, but he holds to this mantra like an oath. Before he famously bought a massive position in Apple stock, he stubbornly avoided the hot tech stocks that were driving the market higher because he admitted he didn't really understand them. Although he may have missed out on some big gains from well-known companies like Nvidia, he's still managed to assemble a portfolio that has absolutely trounced the returns of the S&P 500 for a decades-long stretch. Clearly, the stocks that Buffett does choose to invest in are ones he thoroughly understands, including their profit potential. As of March 2025, Berkshire Hathaway held approximately $126 billion in debt. While that may be a lot of debt in an absolute sense, relatively speaking, it's effectively nothing. Berkshire has cash reserves of almost three times the amount of its debt — giving it net debt of $0 — and it generated over $424 billion in revenue in 2024 alone. Undoubtedly, the debt that Berkshire carries on its books serves an investment purpose, otherwise Buffett, who famously decries debt, would simply pay it off. The same principle should hold true with most investors. Debt should only be used to serve an investment purpose, such as taking out a mortgage to buy a property. Otherwise, you should use your cash reserves to pay that down, particularly if it's high-interest consumer debt, such as on a credit card. While you may never reach the lofty net worth of multi-billionaire Warren Buffett, you can very easily use some of his investment principles to make smart money moves in your own life. And who knows? Given enough time and investment acumen, maybe you too could parlay your strategy into a 10-digit net worth — or at least a solid retirement nest egg. More From GOBankingRates How Much Money Is Needed To Be Considered Middle Class in Every State? This article originally appeared on Warren Buffet's Retirement: 5 Smart Money Moves That Made Him His Massive Fortune Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
